Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

ALAN ALLMAN Stock Went Up By Over 9% So Far On Thursday

Loading stream...

(vianews) - shares of alan allman (cac 40: aaa.pa) rose 9.84% to €9.38 at 13:42 est on thursday, after two successive sessions in a row of losses. cac 40 is dropping 0.51% to €7,094.54, after three sequential sessions in a row of gains. this seems, up until now, a somewhat bearish trend trading session today.

alan allman's last close was €8.98, 44.22% under its 52-week high of €16.10.

about alan allman

alan allman associates provides management consulting services. the company provides research and consulting services to other organizations and primarily serves organizations providing consulting services to various sectors. it was founded in 2009 and is based in issy-les-moulineaux, france.

moving average

alan allman's value is below its 50-day moving average of €9.50 and way below its 200-day moving average of €10.57.

more news about alan allman (aaa.pa).

Categories

stockMarket

Tags

Stock PriceMarket Session NowStock Market NowPrice UpMarket SessionStock Price UpALAN ALLMANStock MarketStockAAA.PA
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com